Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
92 results about "Epidermal Dendritic Cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system.
Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
InactiveUS7030228B1Avoid interactionReduce inflammationLectin superfamilyEnzymologyDiseaseAntigen Binding Fragment
Owner:MILTENYI BIOTEC B V & CO KG
Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
InactiveUS6797480B1Improve isolationBiocidePeptide/protein ingredientsAntigenImmunotherapeutic agent
The present invention relates to receptors for heat shock proteins (HSPs), such as gp96, Hsp70 and Hsp90. The heat shock receptor is associated with the cell membranes of a subset of antigen presenting cells, such as macrophages and dendritic cells. The present invention relates to the use of the heat shock protein receptor positive cells, heat shock protein receptor protein, and heat shock protein receptor genes in methods for screening a molecule for the ability to modulate heat shock protein levels or activities.
Owner:CONNECTICUT HEALTH CENT UNIV OF
Ceramide derivatives as modulators of immunity and autoimmunity
α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Modified Vaccinia virus Ankara for the vaccination of neonates
InactiveUS20060127984A1Promote maturitySafely and efficiently vaccinateViral antigen ingredientsMicrobiological testing/measurementAntigenEpidermal Dendritic Cells
Owner:BAVARIAN NORDIC AS
Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
InactiveUS20120004643A1Improve efficiencySsRNA viruses negative-senseAntibacterial agentsEpidermal Dendritic CellsAntibody antigen
The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Owner:BAYLOR RES INST
Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
InactiveCN101031641AGood effectEffective antigen uptakeTissue cultureVaccinationEpidermal Dendritic Cells
The invention relates to a method for the preparation of efficient antigen-presenting human Gamma Delta T cells, to the Gamma Delta T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human Gamma Delta T cells process antigens and present antigenic peptides to Alpha Beta T cells and induce antigen-specific responses (proliferation and differentiation) in nave Alpha Beta T cells. Gamma Delta T cells are easily purified from peripheral blood, acquire''maturation'' status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell and cytotoxic T cell responses. The Gamma Delta T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.
Owner:UNIV COLLEGE CARDIFF CONSULTANTS LTD
Target peptides for ovarian cancer immunotherapy
TADG-12 and CA125 are two proteins expressed with high specificity in ovarian cancer tumors. They thus would be potential antigens for immunotherapy in ovarian cancer. The invention is based on the discovery of peptides in TADG-12 and CA125 that can be used to induce an autologous T cell response that lyses ovarian cancer cells expressing TADG-12 or CA125. The peptides are contacted with dendritic cells in vitro to generate peptide-loaded dendritic cells. The peptide-loaded dendritic cells are contacted with T cells in vitro to amplify CD8+ T cells that recognize the peptide. At least one CA125 peptide and at least one TADG-12 peptide were found that amplified CD8+ T cells, even from cancer patients, that lysed autologous CA125-expressing or TADG-12-expressing tumor cells. The peptide-loaded dendritic cells can be administered to a cancer patient to amplify CD8+ T cells in vivo that attack the cancer cells. Alternatively, autologous CD8+ T cells can be amplified ex vivo and then infused into the cancer patient.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS
Vaccine immunotherapy for immune suppressed patients
InactiveUS20090180982A1Peptide/protein ingredientsAntipyreticLymphatic SpreadEpidermal Dendritic Cells
Owner:KOHN & ASSOC
Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.
Owner:DENDREON PHARMA LLC
Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
The invention describes the use of dendritic cell vaccines, wherein SHP-1 expression or activity is modulated in the dendritic cell. In particular, the invention provides dendritic cells (DC) transduced with an SHP1-shRNA adenovirus, or dominant negative (dn-SHP-1) or constitutively active (ca-SHP-1), and pulsed with an antigen. The methods and compositions of the invention are used for the prevention and / or treatment of cancers, other cell proliferation diseases and conditions, diseases caused by a pathogen, or autoimmune disorders.
Owner:BAYLOR COLLEGE OF MEDICINE
Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors
ActiveUS8846395B2Generate efficientlyCulture processSkeletal/connective tissue cellsPluripotential stem cellLangerhan cell
Owner:WISCONSIN ALUMNI RES FOUND
Polypeptide and nanometer particles thereof for promoting dendritic cells to take in antigen peptides and applications thereof
ActiveCN103910802AUniform particle sizeGood dispersionPharmaceutical non-active ingredientsAntibody medical ingredientsTreatment effectEpidermal Dendritic Cells
The invention discloses a polypeptide and nanometer particles thereof for carrying antigen peptides, preparation methods and applications thereof, and belongs to the field of biological science and drug carriers. The polypeptide is formed by series connection of an alpha-helix polypeptide, a connecting sequence and an antigen peptide in a covalent bond manner, wherein the amino acid sequence of the alpha-helix polypeptide is FAEKFKEAVKDYFAKFWD, the amino acid sequence of the connecting sequence is GSG, and the connecting sequence of the antigen peptide is KVPRNQDWL. The polypeptide and the nanometer particles prepared from the polypeptides are capable of effectively improving the tumor antigen peptide uptake efficiency of the dendritic cells and promoting the prevention and treatment effect of tumors after the DC (dendritic cell) takes in the antigen peptides.
Owner:HUAZHONG UNIV OF SCI & TECH
Separating material and method for collecting cell or the like using the same
InactiveUS20090239300A1Good film formingConvenient and low cost production methodBioreactor/fermenter combinationsBiological substance pretreatmentsEpidermal Dendritic CellsBody fluid
The present invention provides a novel material useful for selectively isolating a cell such as monocyte and the like or a protein from a body fluid and a production method thereof, a physiological material using the material and an isolation material using the physiological material, as well as a method of harvesting a cell such as monocyte and the like using the isolation material, a method of harvesting a protein and a method of preparing a dendritic cell.
Owner:KANEKA CORP
Artificial skin tissue, artificial skin model and manufacturing method therefor
Provided is a novel method capable of manufacturing an artificial skin model including dendritic cells. A method for manufacturing an artificial skin model includes the following: forming a dermal tissue layer by culturing coated cells in which a cell surface is coated with a coating film containing an extracellular matrix component, so that the coated cells are layered; forming a basal layer including type IV collagen on the dermal tissue layer by bringing type IV collagen into contact with the dermal tissue layer; and forming an epidermal layer by arranging epidermal cells on the basal layer. At least one of the dermal tissue layer and the epidermal layer includes dendritic cells.
Owner:BIOMEDICAL TECH HYBRID +1
Immune tolerance inducer
ActiveUS20150174090A1Good effectHeavy metal active ingredientsBiocideTolerance inductionAutoimmune condition
An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and / or therapeutic agent for allergic disease and a preventive and / or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
Owner:SBI PHARMA CO LTD +1
Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
InactiveUS20100168394A1Modulate differentiationModulate functionAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsEpidermal Dendritic CellsGraft survival
The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.
Owner:DINONA INC
Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
InactiveUS20130183377A1Induced proliferationGenerating long lasting protective immunityAntibacterial agentsPowder deliverySynthetic ImmunogensTrypanosomiasis
The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X1=a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X2=a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.
Owner:COUNCIL OF SCI & IND RES +1
DC cell targeted carrier, nanometer corpuscle and preparation method
InactiveCN101156952AImprove targetingActivity will not be lostPowder deliveryPharmaceutical non-active ingredientsHyperbranched polyesterEpidermal Dendritic Cells
The invention belongs to the pharmaceutical high polymer material field, in particular relates to a dendritic cell (DC cell) targeting carrier, a nano particle, and a preparation method thereof. The DC cell targeting carrier of the invention is a compound which is obtained from a mannan covalence hyperbranched polyester-polyethylene glycol copolymer. Simultaneously, the invention also provides the nano particle which is obtained by preparing the DC cell targeting carrier and a medicine composition which is formed by preparing the effective elements of the encapsulated medicine of the DC cell targeting carrier. At the same time, the invention also provides the preparation method and the purpose of the product. The targeting efficiency of the product of the invention is good, the effect is remarkable, and the security is good; the steps of the method of the invention are simple, the cost is inexpensive, the condition is controllable, and the product is suitable for the mass production.
Owner:SICHUAN UNIV
Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents
InactiveUS20020044930A1Promote resultsHigh serum antibody titersBiocidePeptide/protein ingredientsEpidermal Dendritic CellsImproved method
Owner:BIOGEN INC
Method for production of dendritic cell
InactiveUS20100184214A1Improve abilitiesUseful for immunotherapyArtificial cell constructsBlood/immune system cellsEpidermal Dendritic CellsDc vaccine
The present invention provides methods for producing DCs, which comprise the step of culturing DC precursor cells in the presence of multiple cytokines, dendritic cells produced thereby, and uses thereof. The methods of the present invention enable production of large quantities of DC precursors with a high ability to differentiate into DCs. The present invention enables one to obtain large quantities of DCs from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immunotherapy, treatment of infection, and such. Thus, an enhancement is expected for the effect of DC vaccines.
Owner:DNAVEC CORP
Organic rice flour capable of enhancing immunity of infants
The invention discloses organic rice flour capable of enhancing immunity of infants. A formula comprises organic rice, glucose, hawthorn, salt-processed fructus alpiniae oxyphyllae, medlar, pine nut, composite vitamins and composite minerals. The organic rice flour disclosed by the invention has the advantages that a biological enzymolysis technology is utilized for improving the degree of gelatinization of rice starch, the problems of shortage of enteral amylase of the infants and indigestion caused by intake of non-gelatinized starch can be effectively solved, and the digestive absorption index can be obviously improved in comparison with a traditional rice flour processing technology. An extract of the medlar contains lycium barbarum polysaccharides, has the effect of promoting humoral immunity, cellular immunity and erythrocyte immunity, and can promote the function exertion of mononuclear macrophages, NK (natural killer) cells, plaque forming cells, dendritic cells and cell factors and play a positive role in receptor expression, signal conduction and a nerve-endocrine-immune network.
Owner:JIANGSU DESHANG SCI & TECH PHARMA
Antibacterial nano material with high biocompatibility and preparation method thereof, cell membrane extraction method and membrane-coated particle preparation method
PendingCN112716912AGood biocompatibilityImprove the bactericidal effectAntibacterial agentsMaterial nanotechnologyEpidermal Dendritic CellsFreeze-drying
The invention discloses an antibacterial nano material with high biocompatibility and a preparation method thereof, a cell membrane extraction method and a membrane-coated particle preparation method. The antibacterial nano material is nano-particles wrapped by a cell membrane, the nano-particles are copper iron selenide nano-particles (CuFeSe2), and the cell membrane is a dendritic cell membrane. The preparation method of the antibacterial nanoparticles mainly comprises the following steps: dispersing selenium powder and sodium borohydride powder into 100mL of ultrapure water according to a mass ratio of 1: 1.25-1.3 to obtain a solution A; preparing 0.25 + / -0.005 mmol of CuCl2. 2H2O solution and 0.25 + / -0.005 mmol of FeSO4. 7H2O solution respectively, and injecting the solutions into the solution obtained in the step A after 30 + / -2 minutes according to the volume ratio of 1: 1; and filtering and collecting CuFeSe2 nano particles, and carrying out freeze drying to obtain CuFeSe2 powder. The high biocompatibility and the high sterilization effect are realized.
Owner:NANKAI UNIV
Novel receptor protein and method for diagnosing inflammatory diseases by using the same
InactiveCN1317046AFungiCell receptors/surface-antigens/surface-determinantsWhite blood cellEpidermal Dendritic Cells
Disclosed are a novel seven-pass transmembrane receptor protein found in immature dendritic cells and a DNA encoding the same. Further, disclosed are a replicable recombinant DNA which comprises a replicable expression vector and, operably inserted therein, the above-mentioned DNA; a cell of a microorganism or cell culture (transformant), which is transformed with the above-mentioned replicable recombinant DNA; a seven-pass transmembrane receptor protein which is produced on the cell surface of the above-mentioned transformant; a method for screening a ligand which binds to the above-mentioned seven-pass transmembrane receptor protein, and a method for screening a substance which inhibits the ligand from binding to the seven-pass transmembrane receptor protein; and an antibody which binds to the above-mentioned seven-pass transmembrane receptor protein. The present invention also discloses a method for the diagnosis of an inflammatory disease, such as rheumatism, which comprises determining the amount of the seven-pass transmembrane receptor protein expressed in human leukocytes.
Owner:ASAHI KASEI KK
Preparation of monoclonal antibody to N-myc downstream regulated gene 2 and determination of NDRG2 using protein chip
The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.
Owner:KOREA RES INST OF BIOSCI & BIOTECH
Immunogenic composition and uses thereof
ActiveUS20150150966A1Enhance immune responsePeptide/protein ingredientsOvalbuminEpidermal Dendritic CellsImmunogenicity
Owner:ENA RESPIRATORY PTY LTD
Rapamycin nano-micelle eye drops and preparation method thereof
ActiveCN107115299APrevent immune rejectionOrganic active ingredientsSenses disorderDendritic cellPolyethylene glycol
The invention provides a preparation method of rapamycin nano-micelle eye drops. The preparation method comprises the following steps: mixing a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol grafting polymer, rapamycin, absolute ethyl alcohol and glucose to obtain a mixed solution containing the rapamycin; carrying out evaporation and hydration steps on the mixed solution containing the rapamycin and putting the mixed solution on ice; treating in an ice bath until the mixed solution is transparent, so as to obtain the rapamycin nano-micelle eye drops. A result of the embodiment of the invention shows that after the rapamycin nano-micelle eye drops are used for treating, corneal grafts of mice and rabbits continuously keep transparent; the rapamycin nano-micelle eye drops can be used for effectively prolonging the survival time of the corneal grafts; the rapamycin nano-micelle eye drops can be used for effectively reducing inflammatory cell infiltration, inhibiting corneal edema and maintaining normal structures of the corneal grafts; CD11b+macrophage, Ly6G+neutrophil, CD11c+dendritic cells and CD4+T cells, which are infiltrated in the corneal grafts, are remarkably reduced.
Owner:SHANDONG EYE INST
Dendritic cells obtained from induced pluripotent stem cells (IPSCS)
ActiveUS20140050762A1Induce toleranceBiocideArtificial cell constructsEpidermal Dendritic CellsBiochemistry
Owner:OXFORD UNIV INNOVATION LTD
Method and compositions for obtaining mature dendritic cells
We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or “priming” phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or “differentiation” phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.
Owner:THE ROCKEFELLER UNIV +1
In vitro culture method for promoting maturation of dendritic cells and special culture medium for the same
InactiveCN102851256ALess stimuliImprove survival rateDigestive systemAntiviralsSerum freeDc maturation
The invention discloses an in vitro culture method for promoting maturation of dendritic cells and special culture medium for the method. The invention provides a maturation promoting culture medium prepared from in vitro immature dendritic cells. The method includes mixing R848 and PGE2 with serum-free AIM-V culture medium to obtain a culture medium, the concentration of R848 in the maturation promoting culture medium being (1-10) mu g / mL, the concentration of PGE2 in the maturation promoting culture medium being 1 mu g / mL. The inventive experiment shows that the inventive maturation promoting culture medium is superior to the control standard culture medium. The inventive maturation promoting culture medium has few stimulating factors, strong DC maturation promoting capacity, and high survival rate of DC after maturation promotion.
Owner:PEKING UNIV FIRST HOSPITAL
Method for preparing dendritic calcium hydroxide
InactiveCN101168446AProlong or change properties that are not easy to preserveMechanical properties of reinforcementCalcium/strontium/barium oxides/hydroxidesCalcium hydroxideEpidermal Dendritic Cells
The invention relates to a process for preparing Dendritic Cell calcium hydrate by using water-soluble polyacrylamide template agent. The technical scheme of the invention comprises dissolving 0.4-1.0g / L polyacrylamide into water, adding 0.004-0.008mol soluble calcium salt and 0.008-0.024mol caustic soda solution into the polyacrylamide (PAM) solution, vibrating for four times via ultrasonic wave, to form a calcium hydrate suspension, and then drying the calcium hydrate suspension to prepare Dendritic Cell calcium hydrate particles. The frequency of the ultrasonic wave is 40 KHz while the power is 100W / cm2, the first vibration costs 5min, the second vibration costs 30min, the third vibration costs 4min, and the fourth vibration costs 30min. The product is heated and dried at 50-100DEG C. The invention uses novel synthesis line and technique, finds needed drying substrate, and synthesizes Dendritic Cell calcium hydrate particles. Via the analysis of modern machine, the synthesized calcium hydrate particles have special Dendritic Cell structure, which blending adsorption ability with plastic is improved significantly.
Owner:FUJIAN NORMAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com